瑞莎珠单抗治疗活动性银屑病关节炎的疗效与安全性:随机双盲3期KEEPsAKE 2试验24周结果
KEEPsAKE 2试验纳入对≤2种生物制剂应答不佳或不耐受和/或≥1种传统合成改善病情抗风湿药应答不佳的活动性银屑病关节炎成人患者,随机接受瑞莎珠单抗150 mg或安慰剂皮下注射。第24周瑞莎珠单抗组ACR20应答率显著高于安慰剂组(51.3% vs 26.5%,p<0.001),所有次要终点亦优于安慰剂(p<0.05),耐受性良好。
要点
- 第24周ACR20应答率瑞莎珠单抗组51.3% vs 安慰剂组26.5%(p<0.001)。
- 所有次要终点瑞莎珠单抗组均优于安慰剂组(p<0.05)。
- 严重不良事件发生率瑞莎珠单抗组4.0% vs 安慰剂组5.5%,严重感染分别为0.9% vs 2.3%。
核心结论
- 瑞莎珠单抗治疗对生物制剂和/或传统合成改善病情抗风湿药应答不佳的银屑病关节炎患者,在关键疾病结局方面较安慰剂显著改善且耐受性良好。
研究设计与样本
- 3期随机双盲试验,纳入活动性银屑病关节炎成人患者,按生物制剂应答不佳和/或传统合成改善病情抗风湿药应答不佳分层,随机接受瑞莎珠单抗150 mg或安慰剂皮下注射,于第0、4、16周给药,双盲治疗24周。
- 共444例患者随机分组(瑞莎珠单抗组n=224,安慰剂组n=220),中位年龄53岁(范围23-84岁),206例(46.5%)为生物制剂应答不佳。
主要发现
- 第24周达到ACR20主要终点的患者比例瑞莎珠单抗组为51.3%,安慰剂组为26.5%(p<0.001)。
- 所有次要终点瑞莎珠单抗组均优于安慰剂组(p<0.05)。
- 严重不良事件发生率瑞莎珠单抗组为4.0%,安慰剂组为5.5%;严重感染发生率瑞莎珠单抗组为0.9%,安慰剂组为2.3%。
关键数值与推荐
- 主要终点为第24周达到美国风湿病学会评分改善≥20%(ACR20)的患者比例,瑞莎珠单抗组51.3% vs 安慰剂组26.5%(p<0.001)。
- 瑞莎珠单抗给药方案为150 mg皮下注射,于第0、4、16周给药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response or intolerance to ≤2 biological therapies (Bio-IR) and/or ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR). Results through week 24 are reported here. METHODS: Adults with PsA who were Bio-IR and/or csDMARD-IR were randomised to receive subcutaneously administered risankizumab 150 mg or placebo at weeks 0, 4 and 16 during a 24-week, double-blind treatment period. The primary endpoint was the proportion of patients who achieved ≥20% improvement in American College of Rheumatology score (ACR20) at week 24. Secondary endpoints assessed key domains of PsA and patient-reported outcomes. RESULTS: A total of 444 patients (median age 53 years, range 23-84 years) were randomised to risankizumab (n=224) or placebo (n=220); 206 patients (46.5%) were Bio-IR. At week 24, a significantly greater proportion of patients receiving risankizumab achieved the primary endpoint of ACR20 (51.3% vs 26.5%, p<0.001) and all secondary endpoints (p<0.05) compared with placebo. Serious adverse events were reported for 4.0% and 5.5% of risankizumab-treated and placebo-treated patients, respectively; serious infections were reported for 0.9% and 2.3%, respectively. CONCLUSION: Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR. TRIAL REGISTRATION NUMBER: NCT03671148.
引用
- Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2021. PMID: 34815219. doi:10.1136/annrheumdis-2021-221048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。